SRSF2 and myelodysplastic syndrome: Patients with ASXL1mt manifested with a worse complete remission rate (p = 0.011), and an inferior OS was shown in subgroups with MDS, co‐mutations of RUNX1, SRSF2, or NRAS, as well as mutations in G646W (p < 0.05).